Ocular manifestations of graft-versus-host disease: 10 years’ experience

Figures & data

Table 1 Patient demographics

	n (%)
Male	37 (57.8%)
Female	27 (42.2%)
Caucasian	46 (71.8%)
Hispanic	9 (14.1%)
African–American	5 (7.8%)
Asian	2 (3.1%)
Other	2 (3.1%)

Table 2 Visual acuity

Time point	logMAR acuity	Snellen acuity
Initial presentation	0.386	20/49
Worst point in disease	0.758	20/115
Most recent visit	0.502	20/63

Table 3 Ocular manifestations

	n (%)
Classic ocular GVHD (KCS)	49 (80.3%)
Visually significant cataract	23 (37.7%)
Blepharitis	11 (18.0%)
Ocular hypertension	9 (14.8%)
Filamentary keratitis	6 (9.8%)
Corneal perforation	3 (4.9%)
Herpetic keratitis	2 (3.3%)
Bacterial/fungal corneal ulcer	2 (3.3%)
Optic neuritis/neuropathy	2 (3.3%)
Bilateral anterior uveitis	1 (1.6%)
Endophthalmitis	1 (1.6%)
Serous retinal detachment with choroidal lymphoma	1 (1.6%)
Punctal stenosis	1 (1.6%)

Abbreviations: GVHD, graft-versus-host disease; KCS, keratoconjunctivitis sicca.

Table 4 Treatments for keratoconjunctivitis sicca

	n (%)
Artificial tears	49 (100%)
Topical cyclosporine and/or steroids	35 (71.4%)
Topical cyclosporine	26 (53.1%)
Topical steroids	18 (36.7%)
Autologous serum tears (100%)	15 (30.6%)
Bandage contact lens	10 (20.4%)
Punctal occlusion	8 (16.3%)
Penetrating keratoplasty	3 (6.1%)